Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05190237
Other study ID # MIFI-IE-FS
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 19, 2021
Est. completion date February 7, 2022

Study information

Verified date February 2022
Source Chonbuk National University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was conducted to investigate the efficacy and safety of Fermented soybean(Doenjang powder) on intestinal microflora and immune enhancement.


Description:

This study was a 4 weeks, randomized, double-blind human trial to evaluate the efficacy and safety of Fermented soybean(Doenjang powder) on intestinal microflora and immune enhancement.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date February 7, 2022
Est. primary completion date December 24, 2021
Accepts healthy volunteers No
Gender All
Age group 19 Years to 75 Years
Eligibility Inclusion Criteria: - Adult men and women over 19 and under 75 years - After fully hearing and fully understanding this clinical trials, those who agree to voluntarily decide to participate and to comply with the notice Exclusion Criteria: - If screening shows that the white blood cell(WBC) is less than 3000/? or more than 8000/? - Those who have a body mass index(BMI) of less than 18.5 kg / m^2 or greater than 35 kg / m^2 at the screening - Those who have a clinically significant acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, liver biliary system, kidney and urinary system, neuropsychiatry, musculoskeletal system, inflammatory and hematologic and gastrointestinal disorders - Those who take a medication or health function food that affects your promotion of immunity within 1 month prior to the screening - Those who have received antipsychotic medication within 3 months before screening - Those who alcoholic or drug abuse suspected - Those who participated in other clinical trials within 3 months before screening - Laboratory test by show the following results - Aspartate Transaminase(AST), Alanine Transaminase(ALT) > Reference range 3 times upper limit - Serum Creatinine > 2.0 mg/dL - Pregnancy or breast feeding - Those who doesn't accept the implementation of appropriate contraception of a childbearing woman - Principal Investigator judged inappropriate for participation in study because of Laboratory test result, etc.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
TMD21-16 group
2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
TCD21-55 group
2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
TFD21-1 group
2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks

Locations

Country Name City State
Korea, Republic of Clinical Trial Center for Functional Foods Chonbuk National University Hospital Jeonju Jeollabuk-do

Sponsors (1)

Lead Sponsor Collaborator
Chonbuk National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in intestinal microflora Put more than 1 g of feces in the fecal kit, and perform analysis baseline and 4 weeks
Primary Changes of Natural Killer cell activity Natural Killer cell activity was measured in study baseline and 4 week. A ratio of effector cell and target cell was 50:1, 25:1, 12.5:1.
(Experimental - Effector Spontaneous - Target Spontaneous) / (Target Maximum - Target Spontaneous) × 100
baseline and 4 weeks
Secondary Changes of Interleukin-2, Interleukin-12, Interferon-Gamma and Tumor necrosis factor-alpha For blood Interleukin-2, Interleukin-12, Interferon-Gamma and Tumor necrosis factor-alpha analysis, collect 3 ml of blood in one serum separate tube for 5 ml, leave at room temperature for 30 minutes for clotting, after then centrifuge at 3000 rpm (or 2000 xg) for 10 minutes. baseline and 4 weeks
Secondary Wisconsin Upper Respiratory Symptom Survey-21(WURSS-21) The Wisconsin Upper Respiratory Symptom Survey-21 will investigate on the day of visit(visit 1,2).
The Wisconsin Upper Respiratory Symptom Survey-21 consists of seven stages, including individual symptoms, functional quality of life, and overall improvement. Find the total score of symptoms by obtaining the sum of symptom questions, and the total score of quality of life by obtaining the sum of life questions. Additionally, the sum of the total points of symptoms and quality of life is obtained.
All items of symptom score rank on a seven-point scale(1=very mild and 7=severe), where a higher score means higher severity. The symptom score ranges from 0(Do not have this symptom) to 70.
All items of quality of life score rank on a seven-point scale(1=very mildly and 7=severely), where a higher score means higher severity. The quality of life score ranges from 0(Not at all) to 63.
Therefore, the total score ranges from 0 to 133.
baseline and 4 weeks
Secondary Patient global assessment(PGA) It is a questionnaire in which the study subjects self-evaluate the degree of improvement in immunity improvement 4 weeks after intake compared to before and after intake of human-applied test products. A total of five-step evaluation criteria are used for evaluation, and they are evaluated as very good (1), good (2), constant (3), bad (4), and very bad (5). 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT02814617 - The Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity Phase 2/Phase 3
Completed NCT02244372 - Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity N/A
Completed NCT00990002 - Investigation of A Children's Beverage Containing Different Probiotics N/A
Completed NCT00788021 - Protective Immunity Project 01 N/A
Completed NCT01736787 - Efficacy and Safety of Cauliflower Mushroom Extract on Promotion of Immunity N/A
Recruiting NCT04579588 - Understanding Immunity to the Flu Vaccine in COVID-19 Patients
Completed NCT04798677 - Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine N/A
Completed NCT05162820 - Impact of Solarplast® on Immunity in Active Smokers and Non-smokers N/A
Completed NCT01657656 - Vitamin D Supplementations as Adjunct to Anti-Tuberculosis Drugs in Mongolia N/A
Completed NCT05585021 - Clinical Study on the Effect of Probiotic Compound Powder on the Immunity Improvement of Preschool Children N/A
Recruiting NCT05117385 - The Effect of the Consumption of 4 Botanical Extracts on Immunity in Healthy Adults (B-4-Immune) N/A
Completed NCT04647071 - Allium Extracts on the Incidence of Respiratory Infection Symptoms in Healthy Elderly Volunteers N/A
Completed NCT04031222 - Mechanisms of Inflammation, Immunity, Islet Cell and Intestinal Hormone Changes in Youth at Risk for Diabetes
Completed NCT04010331 - Efficacy and Safety of Nokyong Mixture Extract(CME-PI) on Promotion of Immunity N/A
Completed NCT03067714 - A Clinical Study to Investigate the Effect of a Partially Hydrolysed Infant Formula With Added Synbiotics on Gut Microbiota Composition and Clinical Effectiveness in Infants at High Risk of Developing Allergy Phase 3
Completed NCT04664309 - Understanding Immunity to the COVID-19 Vaccines
Withdrawn NCT06121362 - Effect of Protocatechuic Acid on Biochemical Markers of Immunity Status in Healthy Adults N/A
Recruiting NCT02166931 - BRAND'S® Essence of Chicken in the Promotion of Resilience and Resistance to Stress-associated Cognitive Inhibition N/A
Recruiting NCT00645996 - The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants N/A
Completed NCT03336086 - Effect of Weight Reduction on Immunity Phase 3